Abivax's Obefazimod Achieves All Endpoints in Phase 3 Ulcerative Colitis Trial; NDA Submission Planned for Q4 2026
ABVX has more than doubled off its 52-week low of $5.69 on elevated volume (7.3× avg).
Summary
Abivax announced positive topline results from its Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis, meeting all primary and key secondary endpoints and paving the way for an FDA NDA submission in late 2026.
Key Events · Product Development and Regulatory · ABVX
-
Phase 3 Primary Endpoint Met
Obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at Week 44 in both 25 mg (∆39.3%, p<0.0001) and 50 mg (∆40.3%, p<0.0001) dose regimens for moderate to severely active ulcerative colitis.
-
All Key Secondary Endpoints Achieved
Both obefazimod doses met all key secondary endpoints, including endoscopic improvement, endoscopic remission, HEMI, corticosteroid-free clinical remission, and sustained clinical remission, demonstrating robust efficacy.
-
Favorable Safety Profile
The trial showed an overall favorable safety profile with no new safety signals observed, and the treatment was generally well tolerated over the 44-week maintenance period.
-
NDA Submission Planned
Abivax intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for obefazimod in ulcerative colitis in late fourth quarter of 2026.
Analysis · ABVX · Life Sciences
This filing confirms highly positive Phase 3 maintenance trial results for obefazimod in ulcerative colitis, meeting both primary and all key secondary endpoints with a favorable safety profile. This successful outcome significantly de-risks the drug's path to market and positions Abivax to submit a New Drug Application (NDA) to the FDA in late Q4 2026, moving closer to potential commercialization for a major inflammatory disease.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVX was trading at $90.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $5.69 to $148.83. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.